COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,640 Articles (22,913 medRxiv, 8,727 bioRxiv)

Most recent first Previous |  Page 488: Articles 4871-4880  | Next

Spatiotemporally organized immunomodulatory response to SARS-CoV-2 virus in primary human broncho-alveolar epithelia
Castaneda, D. C., Jangra, S., Yurieva, M., Martinek, J., Callender, M., Coxe, M., Choi, A., Diego, J. G.-B., Lin, J., Wu, T.-C., Marches, F., Chaussabel, D., Yu, P., Salner, A., Aucello, G., Koff, J., Hudson, B., Church, S. E., Gorman, K., Anguiano, E., Garcia-Sastre, A., Williams, A., Schotsaert, M., Palucka, K.
10.1101/2023.03.30.534980 — Posted: 2023-03-31
Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of k18-hACE2 transgenic mice infected with a lethal dose of SARS-CoV-2
Ewart, G., Bobardt, M., Bentzen, B. H., Yan, Y., Thomson, A., Klumpp, K., Becker, S., Rosenkilde, M., Miller, M., Gallay, P.
10.1101/2023.03.29.534854 — Posted: 2023-03-30
Broad and potent neutralizing mAbs are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection
Seow, J., Shalim, Z. A., Graham, C., Kimuda, S., Pillai, A., Lechmere, T., Kurshan, A., Khimji, A., Snell, L., Nebbia, G., Mant, C., Waters, A., Fox, J., Malim, M. H., Doores, K. J.
10.1101/2023.03.30.534872 — Posted: 2023-03-30
NETosis Induced by Serum of Patients with COVID-19 is Reduced with Reparixin or Antibodies Against DEK and IL-8
Kilic, I. B., Yasar, A., Yalim Camci, I., Guzel, T., Karahasan, A., Yagci, T., Cine, N., Kandilci, A.
10.1101/2023.03.30.534873 — Posted: 2023-03-30
Improving mRNA vaccine safety and efficiency with cationized lipid nanoparticle formula
Peng, X., Liao, G., Ren, D., Zhou, Y., Wu, X., Lei, Y., Zhang, Y., Chen, L., He, C., Zhang, Y., Yin, H., Yang, G., Xu, K.
10.1101/2023.03.29.534838 — Posted: 2023-03-30
Younger and Rural Children are More Likely to be Hospitalized for SARS-CoV-2 Infections.
Cantu, R., Sanders, S. C., Turner, G. A., Snowden, J., Ingold, A. K., Hartzell, S. L., House, S., Frederick, D., Chalwadi, U. K., Siegel, E. R., Kennedy, J. L.
10.1101/2023.03.29.23287924 — Posted: 2023-03-30
Total-Body Multiparametric PET Quantification of 18F-FDG Delivery and Metabolism in the Study of COVID-19 Recovery
Wang, Y., Nardo, L., Spencer, B. A., Abdelhafez, Y. G., Li, E. J., Omidvari, N., Chaudhari, A. J., Badawi, R. D., Jones, T., Cherry, S. R., Wang, G.
10.1101/2023.03.26.23287673 — Posted: 2023-03-30
Lasting first impression: Pre-existing immunity restricts mucosal antibody responses during Omicron breakthrough
Selva, K. J., Ramanathan, P., Haycroft, E. R., Reynaldi, A., Cromer, D., Tan, C. W., Wang, L.-F., Wines, B. D., Hogarth, P. M., Downie, L. E., Davis, S. K., Purcell, R. A., Kent, H. E., Juno, J. A., Wheatley, A. K., Davenport, M. P., Kent, S. J., Chung, A. W.
10.1101/2023.03.28.23287848 — Posted: 2023-03-30
Impact of vaccinations, boosters and lockdowns on COVID-19 waves in French Polynesia
Chapman, L. A., Aubry, M., Maset, N., Russell, T. W., Knock, E. S., Lees, J. A., Mallet, H.-P., Cao-Lormeau, V.-M., Kucharski, A. J.
10.1101/2023.03.29.23287906 — Posted: 2023-03-29
Single-cell analysis of bronchoalveolar cells in inflammatory and fibrotic post-COVID lung disease
Mehta, P., Sanz-Magallon Duque de Estrada, B., Denneny, E. K., Foster, K., Turner, C. T., Mayer, A., Milighetti, M., Plate, M., Worlock, K. B., Yoshida, M., Brown, J. S., Nikolic, M. Z., Nair, A., Chain, B. M., Noursadeghi, M., Chambers, R. C., Porter, J. C., Tomlinson, G. S.
10.1101/2023.03.28.23287759 — Posted: 2023-03-29

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).